These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 1780769)
41. Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease. Silke B; Verma SP; Ahuja RC; Nelson GI; Hussain M; Taylor SH Herz; 1984 Dec; 9(6):353-61. PubMed ID: 6510876 [TBL] [Abstract][Full Text] [Related]
42. Effects of verapamil on hepatic glutathione in the rat. Liu J; Miyakawa H; Liu JH; Marumo F; Sato C Res Commun Mol Pathol Pharmacol; 1995 Mar; 87(3):307-14. PubMed ID: 7620823 [TBL] [Abstract][Full Text] [Related]
43. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Kang D; Verotta D; Krecic-Shepard ME; Modi NB; Gupta SK; Schwartz JB Clin Pharmacol Ther; 2003 Jan; 73(1):31-40. PubMed ID: 12545141 [TBL] [Abstract][Full Text] [Related]
44. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Fromm MF; Busse D; Kroemer HK; Eichelbaum M Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178 [TBL] [Abstract][Full Text] [Related]
45. Mechanism of action of verapamil in ischemic heart disease: observations on changes in systemic and coronary hemodynamics and coronary vasomobility. Chew CY; Brown BG; Singh BN; Hecht HS; Schnugg SJ; Wong M; Shah PM; Dodge HT Clin Invest Med; 1980; 3(1-2):151-8. PubMed ID: 7008996 [No Abstract] [Full Text] [Related]
46. [Effects of calcium antagonists (verapamil and nifedipine) on blood levels of calcium and cyclic AMP in humans]. Nami R; Martinelli M; Lo Monaco B; Pizzuti M; Nardi PL; D'Ascenzo G; Gennari C Minerva Cardioangiol; 1981 Jun; 29(6):339-50. PubMed ID: 6269022 [No Abstract] [Full Text] [Related]
47. [Combined obzidan and verapamil treatment of ischemic heart disease patients]. Furkalo NK; Zaĭtseva VI Ter Arkh; 1987; 59(9):120-2. PubMed ID: 3424175 [No Abstract] [Full Text] [Related]
48. [Clinical study of verampamil in the treatment of patients with chronic coronary insufficiency]. Schvacabaja IK; Mjasnikov LA; Metelica VI; Grigorjanc RA; Dubinina LT Arzneimittelforschung; 1970 Sep; 20():Suppl 9a:1478+. PubMed ID: 5536558 [No Abstract] [Full Text] [Related]
49. Left ventricular function in patients with coronary artery disease after verapamil administration. Ferlinz J; Easthope JL; Aronow WS Clin Invest Med; 1980; 3(1-2):63-71. PubMed ID: 7471542 [No Abstract] [Full Text] [Related]
50. [Cross double-blind study with verapamil x placebo in ischemic heart disease with an ergometric test]. Ribeiro JM; Sadi J; Barros FA Arq Bras Cardiol; 1984 Aug; 43(2):139-42. PubMed ID: 6398044 [No Abstract] [Full Text] [Related]
51. [On the clinical trial of a heart and coronary drug]. Eisel K; Kaiser H Ther Ggw; 1968 Feb; 107(2):231-2 passim. PubMed ID: 5718464 [No Abstract] [Full Text] [Related]
52. [Hemodynamic and coronary effects of intravenous verapamil in coronary insufficiency]. Zygelman M; Mérillon JP; Guiomard A; Eustigneff T; Zannier D; Gourgon R Arch Mal Coeur Vaiss; 1981 Jun; 74(6):685-94. PubMed ID: 6794490 [TBL] [Abstract][Full Text] [Related]
53. [Assessment of therapeutic effects of Verapamil by means of an exercise test]. Goch JH; Rec A; Bala T Pol Tyg Lek; 1975 Sep; 30(36):1497-8. PubMed ID: 1161614 [No Abstract] [Full Text] [Related]
54. Clinical trial of a new coronary dilator (verapamil hydrochloride) in ischemic heart disease. Husain SA; Saksena HC; Kothari RP; Marothi PS Indian J Med Sci; 1973 Aug; 27(8):596-600. PubMed ID: 4770896 [No Abstract] [Full Text] [Related]
55. Once-daily verapamil. Dunn JM; Groth PE Lancet; 1984 Dec; 2(8415):1338-9. PubMed ID: 6150346 [No Abstract] [Full Text] [Related]
56. [Effects of verapamil on the functional state of the liver in ischemic heart disease]. Zharov EI; Makeeva LG; Svetova SD; Makarovskiĭ VV; Shafranskiĭ IuA; Vertkina NV Sov Med; 1991; (12):10-3. PubMed ID: 1780769 [TBL] [Abstract][Full Text] [Related]
57. [The use of verapamil in suppositories for treating patients with ischemic heart disease]. Shkliar MB; Soleĭko MB; Alekseeva IP; Kul'chevich LV Vrach Delo; 1990 Aug; (8):13-5. PubMed ID: 2256273 [TBL] [Abstract][Full Text] [Related]
58. [Effects of nicardipine on the functional state of the liver in patients with ischemic heart disease]. Makeeva LG; Svetova SD; Martynov AI; Vertkin AL; Makarovskiĭ VV; Shafranskiĭ IuA Klin Med (Mosk); 1991 Oct; 69(10):42-4. PubMed ID: 1766214 [TBL] [Abstract][Full Text] [Related]
59. [Characteristics of the treatment of ischemic heart disease with delayed-action verapamil]. Zharov EI; Styrova TK; Barinov VG; Martynov AI; Galichenko IV; Sedov VP; Vertkin AL Klin Med (Mosk); 1991 Aug; 69(8):48-50. PubMed ID: 1791709 [TBL] [Abstract][Full Text] [Related]
60. [Verapamil in a single dose, evaluation by means of the ergometric test]. Pereira MH; Brito FS; Pereira CB; Lion MF Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():83-94. PubMed ID: 889475 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]